Skip to main content
Erschienen in: Breast Cancer 6/2019

24.05.2019 | Original Article

Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls

verfasst von: Masahiro Manfuku, Tomohiko Nishigami, Akira Mibu, Katsuyoshi Tanaka, Kazufumi Kitagaki, Kazuhiro Sumiyoshi

Erschienen in: Breast Cancer | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

In breast cancer survivors, multiple risk factors for health-related quality of life (HRQoL) and chronic pain, including cancer treatment-related factors, psychosocial factors, and central sensitization (CS), have been suggested; however, there has been no comparative study between breast cancer survivors with and without pain. This study aimed to compare the demographic characteristics, psychological factors, and CS-related symptoms between breast cancer survivors with pain, those without pain, and healthy controls, and to investigate the relationships of these factors with HRQoL.

Methods

We conducted a cross-sectional survey of 218 women, including patients who underwent breast cancer surgery and adjuvant therapy and healthy women.

Results

Patients were divided into the pain group (n = 42), without-pain group (n = 51), and healthy group (n = 47); thus, among breast cancer survivors, 45% reported chronic pain. The proportion of participants who received breast cancer treatments, such as axillary lymph node dissection and chemotherapy, was higher in the pain group than in the without-pain group (p < 0.05). The Central Sensitization Inventory (CSI) and psychosocial factors in the pain group were higher than those in the without-pain group and healthy group (p < 0.01). The CSI and PCS showed larger effect sizes than treatment-related factors. Moreover, HRQoL was significantly correlated with CSI, PCS, Patient Health Questionnaire-2, and Generalized Anxiety Disorder-2 scale (all, p < 0.01). On multiple linear regression analysis, CSI accounted for 43% of the variance in HRQoL.

Conclusions

CS and pain catastrophizing may be more associated with the development and/or maintenance of persistent pain than treatment-related factors.
Literatur
1.
Zurück zum Zitat Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRefPubMed Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRefPubMed
2.
Zurück zum Zitat Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.CrossRefPubMed Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.CrossRefPubMed
3.
Zurück zum Zitat Schou BI, Smeby NA, Ottesen S, Warncke T, Schlichting E. Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manag. 2014;48:852–62.CrossRef Schou BI, Smeby NA, Ottesen S, Warncke T, Schlichting E. Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manag. 2014;48:852–62.CrossRef
4.
Zurück zum Zitat Juhl AA, Christiansen P, Damsgaard TE. Persistent pain after breast cancer treatment: a questionnaire-based study on the prevalence, associated treatment variables, and pain type. J Breast Cancer. 2016;19:447–54.CrossRefPubMedPubMedCentral Juhl AA, Christiansen P, Damsgaard TE. Persistent pain after breast cancer treatment: a questionnaire-based study on the prevalence, associated treatment variables, and pain type. J Breast Cancer. 2016;19:447–54.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016;4:188. Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016;4:188.
6.
Zurück zum Zitat Bosompra K, Ashikaga T, O’Brien PJ, Nelson L, Skelly J. Swelling, numbness, pain, and their relationship to arm function among breast cancer survivors: a disablement process model perspective. Breast J. 2002;8:338–48.CrossRefPubMed Bosompra K, Ashikaga T, O’Brien PJ, Nelson L, Skelly J. Swelling, numbness, pain, and their relationship to arm function among breast cancer survivors: a disablement process model perspective. Breast J. 2002;8:338–48.CrossRefPubMed
7.
Zurück zum Zitat Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life. Breast Cancer Res Treat. 2018;167:157–69.CrossRefPubMed Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life. Breast Cancer Res Treat. 2018;167:157–69.CrossRefPubMed
8.
Zurück zum Zitat Stubblefield MD, Keole N. Upper body pain and functional disorders in patients with breast cancer. PM&R Funct Rehabil. 2014;6:170–83.CrossRef Stubblefield MD, Keole N. Upper body pain and functional disorders in patients with breast cancer. PM&R Funct Rehabil. 2014;6:170–83.CrossRef
9.
Zurück zum Zitat Nijs J, Leysen L, Adriaenssens N, Aguilar Ferrándiz ME, Devoogdt N, Tassenoy A, et al. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta Oncol. 2016;55:659–63.CrossRefPubMed Nijs J, Leysen L, Adriaenssens N, Aguilar Ferrándiz ME, Devoogdt N, Tassenoy A, et al. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta Oncol. 2016;55:659–63.CrossRefPubMed
10.
Zurück zum Zitat Chapman CR, Vierck CJ. The transition of acute postoperative pain to chronic pain: an integrative overview of research on mechanisms. J Pain. 2017;18:359.CrossRefPubMed Chapman CR, Vierck CJ. The transition of acute postoperative pain to chronic pain: an integrative overview of research on mechanisms. J Pain. 2017;18:359.CrossRefPubMed
11.
Zurück zum Zitat Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-las-Peñas C, Del-Moral-Ávila R, Menjón-Beltrán S, Arroyo-Morales M. Widespread mechanical pain hypersensitivity as a sign of central sensitization after breast cancer surgery: comparison between mastectomy and lumpectomy. Pain Med. 2011;12:72–8.CrossRefPubMed Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-las-Peñas C, Del-Moral-Ávila R, Menjón-Beltrán S, Arroyo-Morales M. Widespread mechanical pain hypersensitivity as a sign of central sensitization after breast cancer surgery: comparison between mastectomy and lumpectomy. Pain Med. 2011;12:72–8.CrossRefPubMed
12.
Zurück zum Zitat Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las-Peñas C, Del-Moral-Ávila R, Arendt-Nielsen L, Arroyo-Morales M. Myofascial trigger points in neck and shoulder muscles and widespread pressure pain hypersensitivity in patients with postmastectomy pain: evidence of peripheral and central sensitization. Clin J Pain. 2010;26:798–806.CrossRefPubMed Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las-Peñas C, Del-Moral-Ávila R, Arendt-Nielsen L, Arroyo-Morales M. Myofascial trigger points in neck and shoulder muscles and widespread pressure pain hypersensitivity in patients with postmastectomy pain: evidence of peripheral and central sensitization. Clin J Pain. 2010;26:798–806.CrossRefPubMed
13.
Zurück zum Zitat Leysen L, Adriaenssens N, Nijs J, Pas R, Bilterys T, Vermeir S, et al. Chronic pain in breast cancer survivors: nociceptive, neuropathic, or central sensitization pain? Pain Pract. 2019;19:183–95.CrossRefPubMed Leysen L, Adriaenssens N, Nijs J, Pas R, Bilterys T, Vermeir S, et al. Chronic pain in breast cancer survivors: nociceptive, neuropathic, or central sensitization pain? Pain Pract. 2019;19:183–95.CrossRefPubMed
14.
Zurück zum Zitat Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain. 2008;137:473–7.CrossRefPubMed Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain. 2008;137:473–7.CrossRefPubMed
15.
Zurück zum Zitat Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2–15.CrossRefPubMed Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2–15.CrossRefPubMed
16.
Zurück zum Zitat Edwards RR, Mensing G, Cahalan C, Greenbaum S, Narang S, Belfer I, et al. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. J Pain Symptom Manag. 2013;46:30–42.CrossRef Edwards RR, Mensing G, Cahalan C, Greenbaum S, Narang S, Belfer I, et al. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. J Pain Symptom Manag. 2013;46:30–42.CrossRef
17.
Zurück zum Zitat Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, et al. The development and psychometric validation of the Central Sensitization Inventory. Pain Pract. 2012;12:276–85.CrossRefPubMed Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, et al. The development and psychometric validation of the Central Sensitization Inventory. Pain Pract. 2012;12:276–85.CrossRefPubMed
18.
Zurück zum Zitat Kregel J, Schumacher C, Dolphens M, Malfliet A, Goubert D, Lenoir D, et al. Convergent validity of the dutch Central Sensitization Inventory: associations with psychophysical pain measures, quality of life, disability, and pain cognitions in patients with chronic spinal pain. Pain Pract. 2018;18:777–87.CrossRefPubMed Kregel J, Schumacher C, Dolphens M, Malfliet A, Goubert D, Lenoir D, et al. Convergent validity of the dutch Central Sensitization Inventory: associations with psychophysical pain measures, quality of life, disability, and pain cognitions in patients with chronic spinal pain. Pain Pract. 2018;18:777–87.CrossRefPubMed
19.
Zurück zum Zitat Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the Central Sensitization Inventory: a systematic review. Pain Pract. 2018;18:544–54.CrossRefPubMed Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the Central Sensitization Inventory: a systematic review. Pain Pract. 2018;18:544–54.CrossRefPubMed
20.
Zurück zum Zitat Caumo W, Antunes LC, Elkfury JL, Herbstrith EG, Busanello Sipmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017;10:2109–22.CrossRefPubMedPubMedCentral Caumo W, Antunes LC, Elkfury JL, Herbstrith EG, Busanello Sipmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017;10:2109–22.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tanaka K, Nishigami T, Mibu A, Manfuku M, Yono S, Shinohara Y, et al. Validation of the Japanese version of the Central Sensitization Inventory in patients with musculoskeletal disorders. PLoS One. 2017;12:e0188719.CrossRefPubMedPubMedCentral Tanaka K, Nishigami T, Mibu A, Manfuku M, Yono S, Shinohara Y, et al. Validation of the Japanese version of the Central Sensitization Inventory in patients with musculoskeletal disorders. PLoS One. 2017;12:e0188719.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Coronado RA, George SZ. The Central Sensitization Inventory and Pain Sensitivity Questionnaire: an exploration of construct validity and associations with widespread pain sensitivity among individuals with shoulder pain. Musculoskelet Sci Pract. 2018;36:61–7.CrossRefPubMedPubMedCentral Coronado RA, George SZ. The Central Sensitization Inventory and Pain Sensitivity Questionnaire: an exploration of construct validity and associations with widespread pain sensitivity among individuals with shoulder pain. Musculoskelet Sci Pract. 2018;36:61–7.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat De Groef A, Meeus M, De Vrieze T, Vos L, Van Kampen M, Geraerts I, et al. Unraveling self-reported signs of central sensitization in breast cancer survivors with upper limb pain: prevalence rate and contributing factors. Pain Physician. 2018;21:E247–56.CrossRefPubMed De Groef A, Meeus M, De Vrieze T, Vos L, Van Kampen M, Geraerts I, et al. Unraveling self-reported signs of central sensitization in breast cancer survivors with upper limb pain: prevalence rate and contributing factors. Pain Physician. 2018;21:E247–56.CrossRefPubMed
24.
Zurück zum Zitat Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early-stage breast cancer. Breast Dis. 2004;21:55–64.CrossRefPubMed Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early-stage breast cancer. Breast Dis. 2004;21:55–64.CrossRefPubMed
25.
Zurück zum Zitat Yu J, Son WS, Lee SB, Chung IY, Son BH, Ahn SH, et al. Uneven recovery patterns of compromised health-related quality of life (EQ-5D-3 L) domains for breast Cancer survivors: a comparative study. Health Qual Life Outcomes. 2018;16:143.CrossRefPubMedPubMedCentral Yu J, Son WS, Lee SB, Chung IY, Son BH, Ahn SH, et al. Uneven recovery patterns of compromised health-related quality of life (EQ-5D-3 L) domains for breast Cancer survivors: a comparative study. Health Qual Life Outcomes. 2018;16:143.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat So WK, Marsh G, Ling WM, Leung FY, Lo JC, Yeung M, et al. Anxiety, depression and quality of life among Chinese breast cancer patients during adjuvant therapy. Eur J Oncol Nurs. 2010;14:17–22.CrossRefPubMed So WK, Marsh G, Ling WM, Leung FY, Lo JC, Yeung M, et al. Anxiety, depression and quality of life among Chinese breast cancer patients during adjuvant therapy. Eur J Oncol Nurs. 2010;14:17–22.CrossRefPubMed
27.
Zurück zum Zitat Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015;156:1003–7.PubMedPubMedCentral Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015;156:1003–7.PubMedPubMedCentral
28.
Zurück zum Zitat Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory—BPI-J. J Pain Symptom Manag. 1998;16:364–73.CrossRef Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory—BPI-J. J Pain Symptom Manag. 1998;16:364–73.CrossRef
29.
Zurück zum Zitat Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing clinically relevant severity levels for the Central Sensitization Inventory. Pain Pract. 2017;17:166–75.CrossRefPubMed Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing clinically relevant severity levels for the Central Sensitization Inventory. Pain Pract. 2017;17:166–75.CrossRefPubMed
30.
Zurück zum Zitat Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.CrossRefPubMed Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.CrossRefPubMed
31.
Zurück zum Zitat Sullivan M, Bishop S, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7:524–32.CrossRef Sullivan M, Bishop S, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7:524–32.CrossRef
32.
Zurück zum Zitat Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010;8:348–53.CrossRefPubMedPubMedCentral Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010;8:348–53.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31.CrossRefPubMed Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31.CrossRefPubMed
34.
Zurück zum Zitat Vahdaninia M, Omidvari S, Montazeri A. What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiatr Epidemiol. 2010;45:355–61.CrossRefPubMed Vahdaninia M, Omidvari S, Montazeri A. What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiatr Epidemiol. 2010;45:355–61.CrossRefPubMed
35.
Zurück zum Zitat Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ. Quality of life in long-term breast cancer survivors. J Clin Oncol. 2013;31:3540–8.CrossRefPubMed Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ. Quality of life in long-term breast cancer survivors. J Clin Oncol. 2013;31:3540–8.CrossRefPubMed
36.
Zurück zum Zitat Andersen LN, Kohberg M, Juul-Kristensen B, Herborg LG, Søgaard K, Roessler KK. Psychosocial aspects of everyday life with chronic musculoskeletal pain: a systematic review. Scand J Pain. 2014;5:131–48.CrossRefPubMed Andersen LN, Kohberg M, Juul-Kristensen B, Herborg LG, Søgaard K, Roessler KK. Psychosocial aspects of everyday life with chronic musculoskeletal pain: a systematic review. Scand J Pain. 2014;5:131–48.CrossRefPubMed
37.
Zurück zum Zitat Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst. 2003;95:263–81.CrossRefPubMed Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst. 2003;95:263–81.CrossRefPubMed
38.
Zurück zum Zitat Bennett EE, Walsh KM, Thompson NR, Krishnaney AA. Central Sensitization Inventory as a predictor of worse quality of life measures and increased length of stay following spinal fusion. World Neurosurg. 2017;104:594–600.CrossRefPubMed Bennett EE, Walsh KM, Thompson NR, Krishnaney AA. Central Sensitization Inventory as a predictor of worse quality of life measures and increased length of stay following spinal fusion. World Neurosurg. 2017;104:594–600.CrossRefPubMed
39.
Zurück zum Zitat Wong WS, Lam HM, Chow YF, Chen PP, Lim HS, Wong S, et al. The effects of anxiety sensitivity, pain hypervigilance, and pain catastrophizing on quality of life outcomes of patients with chronic pain: a preliminary, cross-sectional analysis. Qual Life Res. 2014;23:2333–41.CrossRefPubMed Wong WS, Lam HM, Chow YF, Chen PP, Lim HS, Wong S, et al. The effects of anxiety sensitivity, pain hypervigilance, and pain catastrophizing on quality of life outcomes of patients with chronic pain: a preliminary, cross-sectional analysis. Qual Life Res. 2014;23:2333–41.CrossRefPubMed
40.
Zurück zum Zitat van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology. 2008;17:1137–45.CrossRefPubMed van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology. 2008;17:1137–45.CrossRefPubMed
Metadaten
Titel
Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls
verfasst von
Masahiro Manfuku
Tomohiko Nishigami
Akira Mibu
Katsuyoshi Tanaka
Kazufumi Kitagaki
Kazuhiro Sumiyoshi
Publikationsdatum
24.05.2019
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 6/2019
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00979-y

Weitere Artikel der Ausgabe 6/2019

Breast Cancer 6/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.